SAN FRANCISCO, Feb. 21, 2019 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing innovative gene therapy
products for patients living with serious, life-threatening rare
diseases, will host a conference call and webcast to report its
fourth quarter and full year 2018 financial results and provide a
corporate update on Wednesday, February 27,
2019.
The conference call will be held at 4:30
pm EST, after the market closes. To access a live webcast of
the conference call, please visit the Events & Presentations
page within the Investor + Media section of the Audentes website at
www.audentestx.com. Alternatively, please call (833) 659-8620
(U.S.) or (409) 767-9247 (international) and dial the conference
ID# 1196899 to access the call.
A replay of the live webcast will be available on the Audentes
website for approximately 30 days.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused
on developing and commercializing innovative gene therapy products
for patients living with serious, life-threatening rare
diseases. We are currently conducting
Phase 1/2 clinical studies of our lead product
candidates, AT132 for the treatment of X-linked Myotubular Myopathy
(XLMTM), and AT342 for the treatment of Crigler-Najjar
syndrome. We have two additional product candidates in
development, including AT845 for the treatment of Pompe disease,
and AT307 for the treatment of the CASQ2 subtype of
catecholaminergic polymorphic ventricular tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please
visit www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-release-fourth-quarter-and-full-year-2018-financial-results-and-provide-corporate-update-on-wednesday-february-27-2019-300799393.html
SOURCE Audentes Therapeutics, Inc.